Skip to content

Zimmer Biomet Holdings ZBH Spine — Goodwill

Discontinued — last reported Q4 '18

Similar metrics at other companies

Cognizant logo
CTSHHealth Sciences — Goodwill
$2.92B+0.7%
DaVita logo
DVADE — Goodwill
$72.46M
IR
IRMedical — Goodwill
$203.2M0.0%
Baxter International logo
BAXMedical Products & Therapies — Goodwill
$1.25B+2.0%
Acuity Brands logo
AYIIntelligent Spaces Group Segment — Goodwill
$15M-82.0%
IR
IRBiopharma — Goodwill
$816.6M

Other financials

Income statement

See full
Revenue$2.1B+9.3%
Gross profit$1.5B+11.1%
Operating income$373.2M+27.7%
Net income$238.1M+30.8%
EPS (diluted)$1.22+34.1%

Balance sheet

See full
Cash & equivalents$424.2M-69.4%
Total debt$7.5B+4.1%
Total equity$12.7B+2.2%
Total assets$22.7B+2.4%

Cash flow

See full
Operating cash flow$359.4M-6.1%
CapEx$36.3M-18.6%
Free cash flow$323.1M-4.5%

Valuation

See full
Market cap$17.02B-21.5%
Enterprise value$24.07B-12.7%
P/E22.4×-1.4×
P/S-0.8×

Profitability

See full
Gross margin70%-1.0pp
Operating margin14%-3.0pp
Net margin9.1%-2.8pp
FCF margin17.3%-1.6pp

Returns & leverage

See full
Return on equity6.1%-1.2pp
Debt / equity0.6×0.0×
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Zimmer Biomet Holdings in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Zimmer Biomet Holdings’s 10-K, filed February 22, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does spine — goodwill mean?
The recorded value of intangible assets and acquisition premiums specifically attributed to the Spine business segment.
How do you interpret spine — goodwill?
An increase typically reflects recent acquisitions within the spine sector, while a decrease indicates either asset impairment or the divestiture of spine-related business units.
How does spine — goodwill compare across companies?
Peers in the medical device industry often carry significant goodwill in specialized segments like spine or orthopedics following M&A activity; high levels relative to segment revenue may indicate aggressive acquisition pricing.